SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-077431
Filing Date
2022-07-05
Accepted
2022-07-05 17:13:25
Documents
15
Period of Report
2022-07-05
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2220416d1_8k.htm   iXBRL 8-K 25725
2 EXHIBIT 3.1 tm2220416d1_ex3-1.htm EX-3.1 5806
3 EXHIBIT 99.1 tm2220416d1_ex99-1.htm EX-99.1 5813
7 GRAPHIC tm2220416d1_ex99-1img001.jpg GRAPHIC 17857
  Complete submission text file 0001104659-22-077431.txt   242132

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ttnp-20220705.xsd EX-101.SCH 3039
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ttnp-20220705_lab.xml EX-101.LAB 34476
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ttnp-20220705_pre.xml EX-101.PRE 22599
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2220416d1_8k_htm.xml XML 3727
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 221066312
SIC: 2836 Biological Products, (No Diagnostic Substances)